drugset / Trial / NCT02905864

Liraglutide 3 mg for Knee Osteoarthritis

NCT02905864

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis. Patients will be subjected to a run-in diet intervention phase (week -8 to 0) including a low-calorie diet and dietetic counselling. At week 0 patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.

Timeline

Start
2016-11
Primary completion
2019-02
Completion
2019-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 3 mg Subcutaneous